⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12777784 | 1.00 | — | — | |
| SCHEMBL2074979 | 0.84 | MAPK1 (0.35) | — | |
| SCHEMBL2074977 | 0.84 | MAPK1 (0.35) | — | |
| SCHEMBL6843553 | 0.83 | — | — | |
| SCHEMBL7157666 | 0.83 | — | — | |
| SCHEMBL16666800 | 0.81 | MEN1 (0.35) | — | |
| SCHEMBL10232389 | 0.81 | CRBN (0.38) | — | |
| SCHEMBL15692308 | 0.81 | CRBN (0.38) | — | |
| SCHEMBL21570650 | 0.81 | — | — | |
| SCHEMBL13774695 | 0.81 | MEN1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118546055-A | Preparation method of (1R, 3S, 5S) -3- (4- (5-bromo-2-chlorobenzyl) phenoxy) bicyclo [3.1.0] hexane | 山东科巢生物制药有限公司 | 2024-08-27 | — | — | CN | claimed |
| CN-221182727-U | Preparation device of bicyclo [3.1.0] -3-hexanone | 上海合全药物研发有限公司 | 2024-06-21 | — | — | CN | claimed |
| WO-2024123967-A1 | SARM1 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | SENYA PHARMACEUTICALS, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| US-12636279-B2 | Choline salt forms of an HIV capsid inhibitor | GILEAD SCIENCES, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIV (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260124209-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2026-05-07 | — | — | US | disclosed |
| EP-4727909-A1 | METHODS AND INTERMEDIATES FOR PREPARING COMPOUNDS | VIIV Healthcare UK (No.5) Limited (GB) | 2026-04-22 | — | — | EP | disclosed |
| EP-4720072-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12594267-B2 | Capsid inhibitors for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-12594276-B2 | Inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2026-04-07 | — | — | US | disclosed |
| US-20260078133-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2026-03-19 | — | — | US | disclosed |
| WO-2002076516-A1 | UTILIZATION OF ODORIFEROUS COMPOSITIONS IN ODORIFEROUS CHIPS | SYMRISE GMBH & CO. KG (DE) | 2002-10-03 | — | — | WO | disclosed |
| EP-0413455-B1 | Azabicyclo quinolone carboxylic acids | PFIZER (US) | 1995-06-21 | — | — | EP | disclosed |
| US-5391763-A | 3-aza-bicyclo[3.1.0]hexanes which are intermediates for anti-bacterial azabicyclo quinolone carboxylic acids | PFIZER INC. (US) | 1995-02-21 | — | — | US | disclosed |
| US-5266569-A | Azatricyclo carboxylic acids useful as anti-bacterial agents | PFIZER INC. (US) | 1993-11-30 | — | — | US | disclosed |
| US-5229396-A | Anti-bacterial azabicyclo quinolone carboxylic acids | PFIZER INC. (US) | 1993-07-20 | — | — | US | disclosed |
| US-5164402-A | Bactericides | PFIZER INC (US) | 1992-11-17 | — | — | US | disclosed |
| WO-1991002526-A1 | AZABICYCLO QUINOLONE CARBOXYLIC ACIDS | PFIZER INC. (US) | 1991-03-07 | — | — | WO | disclosed |
| US-3954832-A | 16-And 16,16-methyl and ethyl substituted PGA1 -type compounds | THE UPJOHN COMPANY (US) | 1976-05-04 | — | — | US | disclosed |
| US-3936487-A | RACEMIC MIXTURES, ANTIULCER, ANTICOAGULANT, LABOR INDUCING | THE UPJOHN COMPANY (US) | 1976-02-03 | — | — | US | disclosed |